Search clinical trials for: IBI939 Sintilimab

Total 464 results

Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
Shanghai Zhongshan Hospital
Fudan University

Not yet recruiting

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer

Pancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIB

China
Xin-Hua Xu

Recruiting

A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.

Nonsquamous Non-Small Cell Lung Cancer

China
Saglik Bilimleri Universitesi

Completed

The Effect on Thirst, Nausea-Vomiting and Comfort Levels of Menthol Lozenge Applied After Extubation

Nausea | Vomiting | Thirst

Turkey
Sun Yat-sen University
Xiangya Hospital of Central South University; Nanfang Hospital of Southern... and other collaborators

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

Unresectable Hepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage

China
Sun Yat-sen University

Recruiting

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

Recurrent/ Advanced Stage Endometrial Cancer Patients

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Helsinn Healthcare SA

Completed

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Zhejiang Cancer Hospital

Not yet recruiting

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Second Xiangya Hospital of Central South University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)

Non Small Cell Lung Cancer | Propranolol
Ruijin Hospital

Recruiting

Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis

Gastric Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.
Fortrea

Completed

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) (ORIENT-15)

Esophageal Squamous Cell Carcinoma

France, Spain, Belgium, Australia, United States, China, Hungary
Tianjin Medical University Cancer Institute and...

Active, not recruiting

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV

China
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Xin-Hua Xu

Completed

Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes

Non-small Cell Lung Cancer

China
RenJi Hospital

Not yet recruiting

IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation (iPLENTY-pvtt)

Hepatocellular Carcinoma | Liver Transplant; Complications | Liver Cancer | Portal Vein Thrombosis | Radiotherapy; Complications

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Tang-Du Hospital

Recruiting

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Non Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Squamous NSCLC

China
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Southwest Hospital, China

Recruiting

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study) (RANT)

Hepatocellular Carcinoma Recurrent

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Gastric Adenocarcinoma

China
Zhejiang Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

Breast Neoplasms

China
Fudan University
Zhejiang Cancer Hospital; Xijing Hospital; Shanghai Zhongshan Hospital; Tongji...

Recruiting

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Sarcoma, Soft Tissue

China
Zhou Chengzhi

Unknown

Clinical Trial of Sintilimab Combined With Gemcitabine/Carboplatin Regimen in the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-like Carcinoma

Lung Cancer | Primary Pulmonary Lymphoepithelioma-like Carcinoma

China
Zhujiang Hospital

Recruiting

Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients

Recurrent Glioblastoma

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Microsatellite Stable | RAS Mutation

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Classic Hodgkin's Lymphoma

China
R-Evolution Worldwide S.r.l. Impresa Sociale
University Ghent; National Institute for Medical Research, Tanzania; University... and other collaborators

Not yet recruiting

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis (NeuroSolve)

Neurocysticercosis
Second Affiliated Hospital, School of Medicine,...

Recruiting

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Colorectal Cancer Stage IV

China
Jiuda Zhao

Recruiting

Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer

Breast Cancer

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma

Nasopharyngeal Neoplasms

China
Sun Yat-sen University
Innovent Biologics, Inc.

Active, not recruiting

HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (HAICPD1-HCC)

Hepatocellular Carcinoma

China
Helsinn Healthcare SA

Completed

Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA (MEI-005)

Myelodysplastic Syndrome | MDS

United States
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma (CONTINUUM)

Nasopharyngeal Neoplasms

China
XIANG YANQUN

Active, not recruiting

Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study

Chemotherapy Effect | Metastatic Nasopharyngeal Carcinoma

China
Sun Yat-sen University
Innovent Biologics (Suzhou) Co. Ltd.; CSPC Pharmaceutical Group Limited

Completed

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Esophageal Squamous Cell Carcinoma

China
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users

Nicotine Dependence

United States
Northwestern University
Eisai Inc.

Unknown

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...

United States
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
RenJi Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Prospective, Single-arm, Exploratory Clinical Study of Sintilimab Injection in Combination With Paclitaxel (Albumin-bound) and Gemcitabine in Translational Therapy in Patients With Unresectable Locally Advanced Pancreatic Cancer.

Unresectable Locally Advanced Pancreatic Cancer

China
Galderma R&D

Completed

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

Acne Vulgaris

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
The Central Hospital of Lishui City

Not yet recruiting

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Hepatocellular Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

Non-Small Cell Lung Cancer

China

3

Subscribe